Geron Company Leadership
GERN Stock | USD 2.37 0.02 0.84% |
Geron employs about 141 people. The company is managed by 14 executives with a total tenure of roughly 29 years, averaging almost 2.0 years of service per executive, having 10.07 employees per reported executive. Analysis of Geron's management performance can provide insight into the firm performance.
Shannon Odam President Vice President - Human Resources |
Melissa Behrs President Executive Vice President - Portfolio and Alliance Management |
Geron |
Geron Management Team Effectiveness
The company has return on total asset (ROA) of (0.303) % which means that it has lost $0.303 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6903) %, meaning that it created substantial loss on money invested by shareholders. Geron's management efficiency ratios could be used to measure how well Geron manages its routine affairs as well as how well it operates its assets and liabilities.Geron Workforce Comparison
Geron is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,419. Geron holds roughly 141 in number of employees claiming about 4% of equities under Health Care industry.
Geron Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Geron insiders, such as employees or executives, is commonly permitted as long as it does not rely on Geron's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Geron insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Scott Samuels 2 days ago Acquisition by Scott Samuels of 1350000 shares of Geron at 3.21 subject to Rule 16b-3 | ||
Michelle Robertson over a week ago Acquisition by Michelle Robertson of 110000 shares of Geron subject to Rule 16b-3 | ||
Scarlett John A over two months ago Disposition of 600000 shares by Scarlett John A of Geron at 2.54 subject to Rule 16b-3 | ||
O'farrell Elizabeth G. over three months ago Acquisition by Ofarrell Elizabeth G. of 180000 shares of Geron at 3.88 subject to Rule 16b-3 | ||
Ziegler James over three months ago Disposition of 1600000 shares by Ziegler James of Geron at 4.41 subject to Rule 16b-3 | ||
Scott Samuels over six months ago Acquisition by Scott Samuels of 1350000 shares of Geron at 3.21 subject to Rule 16b-3 | ||
O'farrell Elizabeth G. over six months ago Acquisition by Ofarrell Elizabeth G. of 180000 shares of Geron at 3.88 subject to Rule 16b-3 | ||
Lawlis V Bryan over six months ago Disposition of 35000 shares by Lawlis V Bryan of Geron at 3.75 subject to Rule 16b-3 |
Geron Notable Stakeholders
A Geron stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Geron often face trade-offs trying to please all of them. Geron's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Geron's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joseph MD | Research President | Profile | |
John MD | President Board | Profile | |
Shannon Odam | Vice President - Human Resources | Profile | |
Melissa Behrs | Executive Vice President - Portfolio and Alliance Management | Profile | |
Michelle Robertson | CFO, VP | Profile | |
Olivia Bloom | CFO, Executive VP of Fin. and Treasurer | Profile | |
Andrew Grethlein | Executive VP of Devel. and Technical Operations | Profile | |
Scott Samuels | Chief VP | Profile | |
Faye MD | Executive Officer | Profile | |
Stephen JD | Chief VP | Profile | |
Aron Feingold | Vice Communications | Profile | |
James MBA | Executive Officer | Profile | |
Anil Kapur | Executive Officer | Profile | |
Edward Koval | Executive Officer | Profile |
About Geron Management Performance
The success or failure of an entity such as Geron often depends on how effective the management is. Geron management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Geron management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Geron management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company was incorporated in 1990 and is headquartered in Foster City, California. Geron Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Geron Workforce Analysis
Traditionally, organizations such as Geron use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Geron within its industry.Geron Manpower Efficiency
Return on Geron Manpower
Revenue Per Employee | 1.7K | |
Revenue Per Executive | 16.9K | |
Net Loss Per Employee | 1.3M | |
Net Loss Per Executive | 13.2M | |
Working Capital Per Employee | 1.7M | |
Working Capital Per Executive | 16.7M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.